SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.

In a mouse model of acute ischemic stroke, researchers showed that inhibiting the aggregation of GAPDH, either genetically or ...

The Peptide Therapeutics Market value was US$ $$ billion in 2022. The Peptide Therapeutics Market value is forecast to reach US$ $$ billion by 2032, growing at a compound annual growth rate (CAGR) $% ...

Dysregulation of protein–protein interactions (PPIs) commonly leads to disease. PPI stabilization has only recently been systematically explored for drug discovery despite being a powerful approach to ...

Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission of acid peptic disorders, such as gastro-oesophageal reflux disease. Side effects with respect to ...

Although PPI use was associated with reduced ICU length of stay, it did not shorten total hospital stay duration. Additionally, PPI administration was linked to clinically significant adverse ...

Objective Proton pump inhibitors (PPIs) are drugs used to suppress gastric acid production and treat GI disorders such as peptic ulcers and gastro-oesophageal reflux. They have been considered low ...

Cancer patients receiving ICIs may experience more severe toxicity and have a greater risk of death if they have recently used PPIs, data suggest.

This is the first large‐scale epidemiological study to assess whether proton pump inhibitor use is associated with incident hypertension, and how long‐term use could affect hypertension risk.

Proton pump inhibitors (PPIs) could affect blood pressure regulation by suppressing gastric acid required for the conversion of oral nitrite into nitric oxide. Whether PPI use is associated with ...

Through selected case studies, we highlight the versatility and broad applicability of methylene thioacetal linkage in stabilizing disulfide-containing peptides, positioning it as a compelling ...

This approach enables the selection of peptides that disrupt specific PPIs by linking inhibition to a measurable phenotype (Figure 41 B). This method has allowed identification of mammalian ...